Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter Divests Cell Vax Platform to Nanotherapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Baxter Divests Cell Vax Platform to Nanotherapeutics

Includes Czech production facility and assets for H5N1, H1N1 and seasonal flu vaccines

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxter International has entered into a definitive agreement to sell its Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial terms were not disclosed.
 
The Vero cell platform is an advanced, cell-based technology for vaccine production, including vaccines for H5N1, H1N1 and seasonal flu. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus.
 
Baxter also recently completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer.
 
“The divestiture of the vaccines franchise will allow Baxter BioScience to enhance focus in core therapeutic areas of hematology, oncology and immunology, as it prepares to become an independent biopharmaceutical company,” said Ludwig Hantson, Ph.D., president of Baxter BioScience. “In addition, these transactions provide flexibility to direct resources toward strategic priorities that will drive future growth.”Baxter Divests Cell Vax Platform to Nanotherapeutics
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics